Avian Influenza Clinical Trial
Official title:
A Phase I Cohort-Randomized, Double-Blind, Controlled Trial in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Inactivated Influenza A/H5N8 Virus Vaccine Administered Intramuscularly at Different Dosages Given With or Without AS03 or MF59 Adjuvants: Assessment of Immunological Responses and Lymphocyte Interplay
This is a Phase I cohort-randomized, double-blind, controlled trial designed to assess the safety, reactogenicity, and immunogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine administered at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants. This study will be conducted at 6 sites and enroll 150 (up to 380) males and non-pregnant females, 19 to 64 years old, inclusive who are in good health and meet all eligibility criteria. The entire study duration is approximately 24 months and each subject participation duration is approximately 13 months. The primary objectives are: 1) To assess the safety and reactogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine following receipt of two doses administered intramuscularly at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants approximately 21 days apart. 2) To assess the serum HAI and Neut antibody responses to a monovalent inactivated influenza A/H5N8 virus vaccine following receipt of two doses administered intramuscularly at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants approximately 21 days apart.
This is a Phase I cohort-randomized, double-blind, controlled trial designed to assess the safety, reactogenicity, and immunogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine manufactured by bioCSL administered at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants manufactured by GlaxoSmithKline Biologicals (GSK) and Novartis Vaccines and Diagnostics (NVD), respectively. This study will be conducted at 6 VTEU sites and enroll 150 (up to 380) males and non-pregnant females, 19 to 64 years old, inclusive who are in good health and meet all eligibility criteria. The entire study duration is approximately 24 months and subject participation duration is approximately 13 months. Subjects will be enrolled in one of two cohorts, and within each cohort subjects will be randomized in a 2:2:1 ratio. Subjects in Cohort 1 will be randomly assigned to 1 of 3 treatment arms to receive two doses of the A/H5N8 vaccine at varying antigen dosages (3.75 or 15 mcg HA) with AS03 (30-76 subjects per treatment arm), or to a comparator arm receiving two doses of the A/H5N8 vaccine (15 mcg HA) without adjuvant (15-38 subjects). Subjects in Cohort 2 will be randomly assigned to 1 of 3 treatment arms to receive two doses of the A/H5N8 vaccine at varying antigen dosages (3.75 or 15 mcg HA) with MF59 (30-76 subjects per treatment arm), or to a comparator arm receiving two doses of the A/H5N8 vaccine (15 mcg HA) without adjuvant (15-38 subjects). All subjects will receive the same dosage of vaccine with or without the same adjuvant at both of their first and second study vaccinations, with the exception that subjects in Cohort 1 who do not receive Vaccination 2 prior to February 28, 2017 will receive a second unadjuvanted vaccination with the same antigen dosage as their randomized assignment. All doses will be administered intramuscularly approximately 21 days apart. Primary objectives are: 1) To assess the safety and reactogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine following receipt of two doses administered intramuscularly at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants approximately 21 days apart. 2) To assess the serum HAI and Neut antibody responses to a monovalent inactivated influenza A/H5N8 virus vaccine following receipt of two doses administered intramuscularly at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants approximately 21 days apart. Secondary objectives are: 1) To assess study unsolicited non-serious AEs following receipt of two doses of a monovalent inactivated influenza A/H5N8 virus vaccine administered intramuscularly at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants approximately 21 days apart. 2) To assess medically-attended adverse events (MAAEs), including new-onset chronic medical conditions (NOCMCs), potentially immune-mediated medical conditions (PIMMCs), and all serious adverse events (SAEs) following receipt of two doses of a monovalent inactivated influenza A/H5N8 virus vaccine administered intramuscularly at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants approximately 21 days apart. 3) To assess the serum HAI and Neut antibody responses to a monovalent inactivated influenza A/H5N8 virus vaccine following receipt of one dose administered intramuscularly at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01698060 -
Immunogenicity of ND1.1 by Delivery Directly to the Ileum
|
Phase 1 | |
Completed |
NCT02213354 -
H7N9 Mix and Match With MF59 in Healthy Elderly Persons
|
Phase 2 | |
Completed |
NCT02295813 -
Safety and Pharmacokinetics Study of FBF001
|
Phase 1 | |
Completed |
NCT00561184 -
Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine
|
Phase 2 | |
Completed |
NCT02921997 -
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
|
Phase 2 | |
Completed |
NCT03682120 -
Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza
|
Phase 2 | |
Completed |
NCT00895544 -
Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults
|
Phase 1/Phase 2 | |
Completed |
NCT02251288 -
A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
|
Phase 1 | |
Completed |
NCT02612909 -
A Safety and Immunogenicity Study of IVACFLU-A/H5N1
|
Phase 2/Phase 3 | |
Completed |
NCT02229357 -
Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine
|
Phase 2 | |
Completed |
NCT01150552 -
Studies of Avian Influenza Transmission to Humans in Egypt
|
N/A | |
Completed |
NCT03472976 -
H5N1 With or Without Topical Aldara in Healthy Adults
|
Phase 1 | |
Completed |
NCT01897701 -
A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1
|
Phase 1 | |
Completed |
NCT01107262 -
Avian Influenza Studies In Lebanon
|
N/A | |
Completed |
NCT02839330 -
A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
|
Phase 3 | |
Completed |
NCT00298233 -
High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
|
Phase 2 | |
Completed |
NCT03318315 -
Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4
|
Phase 2 | |
Completed |
NCT03312231 -
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
|
Phase 2 | |
Completed |
NCT03738241 -
2017 A/H7N9 IIV Revaccination
|
Phase 2 | |
Completed |
NCT03589807 -
2013/2017 H7N9 Prime-Boost Interval
|
Phase 2 |